-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, NICE in the United Kingdom recommended Merck Keytruda in combination with the chemotherapy carboplatin and paclitaxel for the treatment of untreated metastatic squamous non-small cell lung cancer (NSCLC)
.
With NICE support, Merck Keytruda became the first NICE-supported immunotherapy to be scored in a first-line setting regardless of PD-L1 expression in combination with chemotherapy
Merck's Keytruda in combination with the chemotherapy carboplatin and paclitaxel received UK NICE support based on the results of the Keynote 407 trial in 559 adults
.
The trial results showed that patients who received Merck's Keytruda and chemotherapy lived a median of 15.
The combination of Merck's Keytruda with the chemotherapy carboplatin and paclitaxel offers lung cancer patients hope of extending life expectancy compared to previous standard treatments
.
With 48,000 new cases of lung cancer each year in the UK, the disease is the third most common form of cancer and the leading cause of death for cancer patients, yet only 16% of those diagnosed survive five years or more
Not long ago, in early January, the US FDA just granted the gene therapy Reqorsa combination therapy Fast Track Designation (FTD), supporting the combination of Reqorsa and Merck Keytruda for the treatment of histologically proven unresectable stage III or IV non-small cells.
Cell lung cancer (NSCLC) patients
.
In the first quarter of 2022, Genprex expects to initiate an open-label, multicenter Phase 1/2 clinical trial to evaluate the efficacy and safety of this treatment combination in this patient population
However, Keytruda's other combination therapy suffered a setback not long ago
.
Merck and Eisai signed a $5.
So far, Keytruda has been approved for as many as 37 additional indications after it was first approved by the U.
S.
FDA in 2014 for the treatment of advanced melanoma
.
Just at the end of December last year, the U.
Sales of blockbuster Keytruda also soared to $14.
4 billion in 2020, with sales of the therapy hitting $12.
6 billion in the three quarters of 2021
.
Analysts pointed out that the total sales of Keytruda therapy in 2021 are expected to reach 17 billion US dollars
Reference source: Merck's Keytruda scores key NICE sign-off for first-line NSCLC indication
